In a conference call, President
and CEO Bill Hawkins stated:
"Endeavor is the first new
drug eluting stent approved for use in the US market in over
four
years and customer reaction has been very positive....
"Endeavor’s
compelling safety and efficacy profile was further validated
last week when four year data from
the Endeavor II pivotal trial and one year data from the 8,000
patient eFive registry were presented at the EuroPCR conference.
Endeavor’s
safety profile is now undeniable – even out to four
years, and its efficacy has been validated once again – even
in real world patients.
"Physician acceptance is reflected in
the market share that Endeavor gained in its first three months
on the US market. We estimate Endeavor captured an average
of 19% of the US market during the fourth 5/20/2008 4 quarter
and
exited the quarter above 20% market share." |
